51572-54-4

Usage

Functional groups

Carboxylic acid, Bromine substituent, Ester

Structure

Cyclopentane ring with a bromine atom at the 1-position and a carboxylic acid group at the 1-position, esterified with a methyl group

Physical state

Colorless liquid

Odor

Pungent

Usage

Organic synthesis, pharmaceutical research (building block for biologically active compounds)

Hazards

Health and environmental hazards (should be handled with care in a controlled laboratory environment)

Safety

Primarily used in laboratory settings due to potential hazards

Appearance

Colorless liquid with a pungent odor

Upstream product

• 3400-45-1 cyclopentanecarboxylic acid 
• 101944-75-6 dimethoxymethylene-cyclopentane 
• 7726-95-6 bromine 
• 51354-79-1 (trimethoxymethyl)cyclopentane 
• 67-56-1 methanol 
• 56447-23-5 1-bromo-1-cyclopentanecarboxylic acid chloride 
• 4524-93-0 Cyclopentanecarboxylic acid chloride 

Downstream Products

• 1560-11-8 cyclopent-1-enecarboxylic acid 
• 807336-32-9 methyl 1-isobutyrylcyclopentanecarboxylate 
• 845727-55-1 methyl 1-(cyclohexylcarbonyl)cyclopentanecarboxylate 
• 851225-31-5 1-(4-bromo-2-methylphenoxy)cyclopentanecarboxylic acid methyl ester 
• 851225-32-6 1-(2-methyl-4-triisopropylsilanylsulfanylphenoxy)cyclopentanecarboxylic acid methyl ester 
• 851225-34-8 1-{2-methyl-4-[3-(4-trifluoromethoxyphenyl)[1,2,4]thiadiazol-5-ylmethylsulfanyl]phenoxy}cyclopentanecarboxylic acid methyl ester 
• 634172-74-0 methyl 1-(1-bromocyclohexylcarbonyl)cyclopentanecarboxylate 

Relevant academic research and scientific papers

HINDERED DISULFIDE DRUG CONJUGATES

The invention relates generally to disulfide drug conjugates wherein a linker comprising a sulfur-bearing carbon atom substituted with at least one hydrocarbyl or substituted hydrocarbyl is conjugated by a disulfide bond to a cysteine sulfur atom of a targeting carrier, and wherein the linker is further conjugated to a drug moiety. The invention further relates to activated linker-drug conjugates suitable for conjugation to a targeting carrier by a disulfide bond. The invention further relates to methods for preparing hindered disulfide drug conjugates.

Reaction of methyl 1-bromocycloalkanecarboxylates with zinc and benzoin

The Reformatsky reagents derived from methyl 1-bromocyclohexane-or 1-bromocyclopentanecarboxylate and zinc add to benzoin to afford the corresponding 4-hydroxy-3,4-diphenyl-2-oxaspiro[4.5]decan-1-one and 4-hydroxy-3,4-diphenyl-2-oxaspiro[4.4]nonan-1-one.

Iridium(I)-catalyzed vinylic C-H borylation of 1-cycloalkenecarboxylates with bis(pinacolato)diboron

Ir(i)-catalyzed C-H borylation of 1-cycloalkenecarboxylic derivatives with bis(pinacolato)diboron affords various alkenylboronates with functional groups in excellent yields. This reaction was also used in a one-pot borylation/Suzuki-Miyaura cross-coupling procedure.

2-Amino-1,3-thiazol-4(5H)-ones as potent and selective 11β- hydroxysteroid dehydrogenase type 1 inhibitors: Enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice

11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) has attracted considerable attention during the past few years as a potential target for the treatment of diseases associated with metabolic syndrome. In our ongoing work on 11β-HSD1 inhibitors, a series of new 2-amino-1,3-thiazol-4(5H)-ones were explored. By inserting various cycloalkylamines at the 2-position and alkyl groups or spirocycloalkyl groups at the 5-position of the thiazolone, several potent 11β-HSD1 inhibitors were identified. An X-ray cocrystal structure of human 11β-HSD1 with compound 6d (Ki = 28 nM) revealed a large lipophilic pocket accessible by substitution off the 2-position of the thiazolone. To increase potency, analogues were prepared with larger lipophilic groups at this position. One of these compounds, the 3-noradamantyl analogue 8b, was a potent inhibitor of human 11β-HSD1 (Ki = 3 nM) and also inhibited 11β-HSD1 activity in lean C57Bl/6 mice when evaluated in an ex vivo adipose and liver cortisone to cortisol conversion assay.

Synthesis and identification of [1,2,4]thiadiazole derivatives as a new series of potent and orally active dual agonists of peroxisome proliferator-activated receptors α and δ

Cardiovascular disease is the most common cause of morbidity and mortality in developed nations. To effectively target dyslipidemia to reduce the risk of cardiovascular disease, it may be beneficial to activate the peroxisome proliferator-activated recept

4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs

The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.